Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fulcrum Therapeutics Announces License Agreement With Sanofi For Losmapimod in Facioscapulohumeral Muscular Dystrophy, Fulcrum Will Receive An Upfront Payment Of $80M And Is Eligible To Receive $975M In Potential Milestones

Author: Benzinga Newsdesk | May 13, 2024 06:04am

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ―

Posted In: FULC SNY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist